… KRAS G12C is the most prevalent KRAS mutation in NSCLC and is present in ∼13% of …
restored the sensitivity of KRAS-mutant NSCLC to MEK inhibition and induced senescence and …

… MEK inhibition in the NRAS and KRAS mutant setting [27–29]. Together these findings indicate
that in the context of MEK inhibition, … combination of MEK inhibitors with ERK inhibitors as …

… allosteric MEK inhibitor that also blocks RAF phosphorylation of MEK, … MEK inhibitors (57).
VS-6766 is currently studied in combination with the FAK inhibitor defactinib in KRAS-mutated …

… and MEK inhibitor combination was limited to cells with wild-type KRAS. To determine whether
… As KRAS mutations are reported so prevalently in pancreatic cancer, our study does raise …

… outcomes in both KRAS and BRAF mutant cell lines treated with MEK inhibitors. In an in …
that sensitivity to MEK inhibitors was specific for cell lines with the single BRAF mutation V600E.…

… -MEK targeted therapies. Here, we investigated a bypass mechanism of resistance … MEK
inhibition in KRAS CRC. We found that KRAS mutant CRC cells with refametinib, MEK inhibitor, …

… of an unsuspected NRAS-mutant leukemia in a patient with … However, whether the effect
of MEK inhibition in vivo is of … The presence of an activating KRAS mutation in this patient's …

… for KRAS mutant cancers and discuss the resistance mechanisms of KRAS mutant therapy
… NSCLC to MEK inhibition and increase inactive GDP-bound KRAS. A triplet combination of …

… inhibition of its downstream kinase MEK. In our study, patients with KRAS mutations received
the MEK inhibitor… only patients to receive twice daily inhibition, the recommended dosing for …

… Inhibitors of the PI3K/mTOR (mammalian target of rapamycin) pathway may be active in
cancers with PI3K mutations and, when combined with MEK inhibitors, may effectively treat …